Catalyst Pharmaceutical Partners, Inc. Company Profile | CPRX Company Information

ejyceh.wordpress.com
We are a biopharmaceutical company focused on the development and commercializationb of prescription drugs for the treatment of drug addictionand obsessive-compulsivew disorders. Our initial producf candidate is CPP-109, which is our version of the chemicalcompouns gamma-vinyl-GABA, commonly referred to as We are currently conducting a clinical trial evaluatinf the use of CPP-109 in the treatmeng of cocaine addiction, and a proof-of-concept studu evaluating the use of CPP-109 in the treatmeny of methamphetamine addiction.
We also believe that CPP-109 has the potentialk to treat other including addictionsto nicotine, prescription pain alcohol, and marijuana, as well as obsessive-compulsivr disorders such as obesity and compulsiv e gambling. We intend to develop CPP-109 to treat othee forms of addiction, such as those describefd above, subject to the availability of funding for such DuringJuly 2007, we initiated a randomized, placebo-controlled U.S. Phase II clinical trial in patientsw withcocaine addiction. During June 2008, we initiatede a similar U.S.
Phase II clinical trial evaluating CPP-10i9 as a treatment for methamphetamine addiction which was subsequentlyu converted into asmaller proof-of-concept study (see Recent Developmenta section below for a discussion of the status of the cocaine trial and methamphetamine proof-of-concept study).